








FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No.  056291-5039		Client Ref.  <div style="text-align: center;">  </div>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Applicant: PEARS et al.					
				Appln. No.: 09/889,414					
				Filing Date: November 13, 2001					
Date: March 10, 2004		Page 1 of 1		Examiner: Meller, Michael V.		Group Art Unit: 1654			
<b>U.S. PATENT DOCUMENTS</b>									
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)			
AR									
BR									
CR									
DR									
ER									
FR									
<b>FOREIGN PATENT DOCUMENTS</b>						English Abstract		Translation Readily Available	
Document Number	Date MM/YYYY	Country	Inventor Name			Enclosed	No	Enclosed	No
GR									
HR									
IR									
JR									
KR									
LR									
MR									
NR									
OR									
PR									
<b>OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)</b>									
QR	 Hunninghake, "HMG CoA reductase inhibitors", Current Opinion in Lipidology 1992; 3:22-28 (cited in the specification at page 3, lines 11-12).								
RR	 Miller et al., "Clinical Pharmacokinetics of Fibrates", Clin Pharmacokinet 1998 Feb; 34(2): 155-162.								
SR	 Williams et al., "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors", Clin Pharmacokinet 2002; 41(5): 343-370.								
TR									
UR									
VR									
WR									
XR									
Examiner: 				Date Considered: 					
<b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									